espite impressions to the contrary, federal officials plan to pursue drug makers for illegal marketing, according to one Department of Justice official who recently provided a roadmap for those seeking to identify bad behavior.

At issue is off-label marketing, a contentious topic that has resulted in huge fines paid by numerous drug makers over the years and is now at the center of a free speech struggle between the pharmaceutical industry and the Food and Drug Administration.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.